Abstract
Lowering of the blood pressure limit that represents adequate control of hypertension from 140/90 mmHg to 130/85 mmHg has inevitably worsened the recorded rates of control among hypertensive patients: patients who were considered controlled at 140/90 mmHg are no longer considered controlled, so the percentage of controlled patients has decreased. Also, significantly, the lower target for blood pressure has created a greater challenge for physicians, who were already having difficulty achieving the 140/90 mmHg goal in their patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156:1969–78.
Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14(3):286–92.
Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens 1999;12:73S–79S.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services. NIH Publication No. 04-5230. Bethesda, MD: National Institutes of Health, August 2004.
Neutel JM Combination therapy and the treatment of hypertension. Cardiology Special Edition 2003; 9(1 of 2):11–15.
Holzgreve H. Combination versus monotherapy as initial treatment in hypertension. Herz 2003; 28(8):725–32.
Food and Drug Administration, Center for Drug Evaluation and Research. Summary Minutes of the Cardiovascular and Renal Drugs Advisory Committee meeting on April 18, 2007. http://www.fda.gov/OHRMS/DOC KETS/AC/07/minutes/2007-4287 m-minutesfinal. pdf. Last accessed May 2011.
Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens 2002; 15:550–6.
Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy with amlodipine besylate/benazepril hydrochloride for lowering systolic blood pressure in stage 2 hypertension. Am J Geriatr Cardiol 2006; 15(3):142–50.
Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens 2005; 7(11):641–6; quiz 647–8.
Neutel JM, Smith DH, Weber MA, Nwose OM, Schofield L, Gatlin M. Management of isolated vs. predominantly systolic hypertension: results of the systolic evaluation of Lotrel efficacy and comparative therapies (SELECT) study. Am J Hypertens 2004; 17:184A (poster P-411).
Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens 2008; 22:266–74.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Healthcare
About this chapter
Cite this chapter
Neutel, J. (2011). Combination Therapy as First-Line Treatment. In: Combination Therapy in Hypertension. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-908517-28-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-908517-28-9_6
Published:
Publisher Name: Springer Healthcare, Tarporley
Print ISBN: 978-1-908517-25-8
Online ISBN: 978-1-908517-28-9
eBook Packages: MedicineMedicine (R0)